Every material Form 8-K EXAGEN INC. has filed with the SEC since April 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Exagen reported second-quarter 2026 revenue of $19.9 million, up 16% from $17.2 million a year earlier, and a net loss of $3.2 million, down from $4.4 million. The company also raised its full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million, which signals higher expected sales for the year.
Q2 2026 revenue was $19.9 million, up from $17.2 million in Q2 2025.
Net loss narrowed to $3.2 million from $4.4 million, which the company describes as a reduction of nearly 30%.
Adjusted EBITDA loss was $0.1 million, compared with $1.7 million a year earlier.
Full-year 2026 revenue guidance raised to $72 million-$75 million from $70 million-$73 million; cash and cash equivalents were $24.6 million at June 30, 2026.
Exagen reported first-quarter 2026 revenue of $17.3 million, up 12% from a year earlier, and reaffirmed full-year 2026 revenue guidance of $70 million to $73 million. The net loss widened to $3.97 million from $3.75 million, though the loss per share narrowed to $0.17 from $0.20 as the share count rose.
Revenue was $17.3 million, up from $15.5 million in the first quarter of 2025.
Net loss was $3.97 million, compared with $3.75 million a year earlier; net loss per share was $0.17 versus $0.20.
Full-year 2026 revenue guidance of $70 million to $73 million was maintained.
Cash and cash equivalents were $21.5 million at March 31, 2026, down from $32.2 million at December 31, 2025.
Exagen director Ana Hooker resigned from the Board, including her Audit Committee seat and chair role on the Nominating and Corporate Governance Committee, effective April 17, 2026. The filing says the resignation was not due to any disagreement with the company on its operations, policies or practices, and the board was reduced from eight to seven members.
Ana Hooker resigned from the Board effective April 17, 2026, the date she notified the Board.
Hooker was a member of the Audit Committee and chair of the Nominating and Corporate Governance Committee.
Board size decreased from eight to seven members as of the effective time.
The filing states no disagreement with the company on operations, policies or practices was the reason for the resignation.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every EXAGEN INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →